Compare Novartis AG (NVS) vs Thomson Reuters Corp (TRI) Price & Performance

Novartis AGTrade

Thomson Reuters CorpTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs Thomson Reuters Corp — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Thomson Reuters Corp trades at $90.98 (market cap $41.28B). The key difference: Novartis AG is far larger — about 7× Thomson Reuters Corp's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.

	NVS	TRI
Market Cap	$290.25B	$41.28B
Sector	Health	Industrials
52-Week High	$168.62	$205.54
52-Week Low	$113.50	$76.55
Enterprise Value	$330.27B	$43.24B
Dividend Yield	3.17%	2.75%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 23 hours agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

TRI

Ocado Group misses earnings estimates, shares hit 13-year low amid operational challenges.Danny Green · 4 days agoBearish View details →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

About Thomson Reuters Corp

Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.